Clinical benefit was seen in 6 of 36 (17%) assessable subjects, among which 5 were affected by ACC with evidence of Notch1 pathway activation, 2 with partial response and 3 prolonged disease stabilization (>6 months) [102]. Here, NOTCH1 is linked to adrenal cortex carcinoma.